BioSpace News Archive

Foghorn® Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced management’s participation in the following investor conferences in August.

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported second quarter and year-to-date 2022 financial results and provided a corporate update.

SCYNEXIS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s submission of a supplemental New Drug Application (sNDA) to expand the label of BREXAFEMME® (ibrexafungerp tablets) to include the prevention of recurrent vulvovaginal candidiasis (RVVC).

Qualigen Therapeutics, Inc. today announces it has completed its in vivo efficacy analysis of QN-247 in solid tumors.

Rubedo Life Sciences , a biopharmaceutical company pioneering first-in-class therapies for chronic age-related diseases targeting the senescent cells that drive cellular aging, today announced the appointment of veteran biotech executives Ali Siam as Chief Business Officer and seasoned drughunter Ofir Moreno, Ph.D., as Senior Vice President, Drug Discovery.

As part of its continued commitment to expand the benefits of next-generation sequencing (NGS), Thermo Fisher Scientific is now accepting submissions for the fifth round of the Oncomine Clinical Research Grant program.

GreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies’ mRNA production partnership.

BrainCheck Inc., developer of an innovative digital cognitive assessment and care platform, announced an Investigator Initiated Research Grant Program to help fund research for evaluation, diagnosis, treatment and care for brain related disease.

Renegade.bio, an LGBTQ-owned public benefit corporation, announced today that it has begun processing highly sensitive and accurate, polymerase chain reaction (PCR) monkeypox tests for San Francisco and California at large, delivering test results in 24 hours through partnerships with surrounding clinics and hospitals.

Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, announced financial results for the fiscal year ended March 31, 2022.